IQVIA Holdings Inc. (IQV) Offers Impressive Upside Despite AI-Linked Threats

IQVIA Holdings Inc. (NYSE:IQV) is one of the 10 best life sciences stocks to buy according to hedge funds.

On February 19, Jailendra Singh from Truist Financial reiterated his Buy rating for IQVIA Holdings Inc. (NYSE:IQV). He lowered the price target on the stock from $290 to $274, which still offers an impressive upside potential of more than 65% despite the revision.

Singh’s price target revision followed the company’s fourth-quarter results, prompting the firm to adjust its model. These adjustments incorporate a re-segmentation for the company, as well as a reduction in the forward EBITDA multiple projections, from 14x to 13x. They also take into account the AI-related uncertainties in the near-term.

On February 17, Charles Rhyee from TD Cowen reaffirmed his Hold rating on IQVIA Holdings Inc. (NYSE:IQV) and lowered the price target from $245 to $174. The firm revised its model following the fourth quarter announcements. He acknowledged that while AI poses potential risks to the segment, these are likely to emerge over the long-term. But for now, the impact on CROs remains uncertain.

IQVIA Holdings Inc. (NYSE:IQV) delivers clinical research services, advanced analytics, commercial insights, and market intelligence to healthcare and life sciences segments worldwide. The company covers end-to-end clinical trials, offering protocol design, site selection, recruitment, and data analysis. It also offers cloud-based commercial solutions such as CRM, contract sales, and analytics.